ViVE 2026: The AI, RCM, and Vertical Health Tech Investors Are Backing

ViVE 2026 didn’t feel like an AI hype show. It felt like a filter separating the healthcare AI ideas that actually create value from the ones that never make it past a demo.

Across investor panels, health system case studies, and the show floor, one theme was unmistakable: AI that cuts labor cost, improves margins, and fits into real workflows is in. Everything else is noise.

ViVE 2026 made one thing clear: the market has shifted from “AI that impresses” to AI that pays for itself and survives budget scrutiny.

 

Why ViVE 2026 Felt Different

• Health systems came with real budget constraints, not exploratory curiosity.
• Investors pushed for unit economics, not user growth.
• AI vendors emphasized deployment, integration, and ROI, not model specs.
• The show floor felt more like an operator’s conference than a futurist expo.

 

Here’s what stood out from our trip.

1. AI that cuts labor cost, not just writes notes

The bar for AI in healthcare has moved from “this is impressive” to “this pays for itself in 6–12 months.”

Investors and health system leaders repeatedly emphasized:

• Ambient AI scribes like Abridge and Suki that actually reduce documentation time and clinician burnout, not just generate notes in a vacuum.
• Prior authorization automation from platforms like Notable that shortens cycle time and lowers manual FTE load.
• Coding, denial management, and RCM copilots such as CodaMetrix that measurably improve yield per FTE.

Ambient documentation, in particular, dominated many AI-focused sessions with live health system case studies showing lower clinician time per encounter and faster note completion, not just pilot-level anecdotes.

The expectation now: if your AI is in the labor loop, it should clearly reduce hours, headcount, or overtime and you should be able to quantify that on a slide.

2. Revenue cycle & margin recovery: the “boring but durable” AI

ViVE’s investment conversations had a strong financial realism. Health systems are under margin pressure, and anything that improves cash flow gets attention.

Investors and RCM leaders highlighted AI’s role in:

• Improving claim acceptance and first-pass clean claim rates, with platforms such as Waystar and R1 RCM.
• Predicting and preventing denials before submission, including tools like Cedar and AKASA.
• Identifying underpayments and missed contract opportunities.
• Modeling payer contracts and revenue scenarios.

Recent research shared around the conference showed that AI and automation are now top investment priorities for most revenue cycle leaders, specifically to stabilize financial performance.​

Nobody called RCM glamorous. But they did call it durable,exactly the profile institutional investors prefer in 2026.

3. Clinical AI: outcomes, FDA, and reimbursement or don’t bother

Clinical AI is growing up, and ViVE made that very clear.

Panels on radiology, sepsis, oncology, and risk stratification for value-based care converged on the same checklist:

• Regulatory clarity: Is there an FDA pathway (510(k), de novo)? What claims are you actually making?
• Outcomes data: Can you show impact on readmissions, time-to-diagnosis, LOS, or adverse events?
• Reimbursement: Is there a CPT, DRG, or value-based care alignment that makes this billable or economically rational?

At ViVE, validated imaging and triage tools such as Aidoc, Viz.ai, Cleerly, and Caption Health fit this pattern: FDA pathways, outcomes data, and clear reimbursement stories.

A great example from the floor: Delphi-MD from QuantalX, which has FDA de novo clearance as a first-in-class device for direct brain function assessment at the point of care. It’s positioned as a functional complement to MRI/CT — essentially an “EKG for the brain” — with real diagnostic and management implications across dementia, movement disorders, and psychiatric conditions.

The takeaway: “We have a model” is noise. “We have a cleared, clinically validated, and billable tool” is signal.

What surprised us in clinical AI

• Fewer “GPT‑wrapped” demos than last year — founders came with FDA pathways, not prompts.
• More cross‑disciplinary teams (clinicians + ML + regulatory) presenting together.
• A shift toward multimodal inputs (signals, imaging, labs, notes) instead of single‑source models.
• A clear expectation that clinical AI must tie to reimbursement or risk‑based contracts.

4. Data plumbing and interoperability: infra is back in style

ViVE 2026 also underscored an old truth: AI is only as good as the data it can reach. The agenda and partner activations pointed heavily toward interoperability and data infrastructure.

Key themes:

• FHIR-native data platforms such as Redox, Health Gorilla, and Particle Health to normalize and expose clinical data in real time.
• EHR overlay layers that sit on top of Epic/Cerner to make insights actionable without replacing core systems, with players like Redox and Datavant often in the stack.
• Real-time streaming architectures for event-driven alerts, population health, and AI-triggered workflows.

Big tech + health system partnerships were everywhere — focused less on flashy models and more on building the pipes and governance layers that make multi-modal AI reliable at scale.

Infra isn’t a side story in this cycle; it’s back as a primary investment theme.

5. Cybersecurity: from “IT problem” to board-level risk

With major ransomware events still fresh, ViVE’s cybersecurity track felt more urgent than in past years.

The conversations emphasized:

• AI-driven anomaly detection on clinical networks and medical devices, from vendors like Claroty, Armis, and Cynerio.
• Zero-trust architectures tailored for sprawling hospital environments.
• Identity and access management that spans EHRs, cloud providers, and third-party vendors, increasingly involving platforms such as Palo Alto Networks.

This category is now framed as “mandatory spend” — a mission-critical line item, not discretionary tech. Investors like that, because budget for security tends to be more stable even in down cycles.

What investors asked repeatedly

• “How fast does this reduce labor cost?”
• “What’s the integration path into Epic/Cerner?”
• “Show me the before/after workflow.”
• “What’s the payback period?”
• “Is this a feature, a workflow, or infrastructure?”

6. Vertical AI: deep in one specialty

Another pattern: instead of broad “AI for healthcare,” more serious capital is flowing toward deep, vertical plays in specific specialties.

Some of the most interesting products we saw or discussed fell into this bucket:

• Behavioral Health / Sleep — MyWaves
  A non-medical, wellness-focused solution that records one night of your brainwaves, extracts delta (slow-wave) activity, and turns it into personalized audio you listen to nightly. The goal: help users fall asleep faster and increase restorative sleep, offered via subscription.

 

• Psychiatry — PMH Scribe
  A psychiatric mental health AI scribe designed specifically for psychiatrists, counselors, and PMHNPs — tuned to that documentation style and workflow, not generic primary care.

• Cardiology / Critical Care — Retia Medical
  Cardiovascular intelligence software that uses existing bedside signals (blood pressure, pulse oximetry, ECG) to generate advanced hemodynamic insights, detecting early circulatory deterioration in high-risk patients. Recent FDA clearance for Argos Infinity extends its reach across high-risk surgical and critical care environments.

 

In all of these, vertical depth — clinical nuance, workflow fit, and evidence — matters more than being a horizontal “AI platform.”

7. Value-based care & employer-focused plays

Value-based care (VBC) showed up throughout ViVE’s agenda, not as a buzzword, but as an infrastructure category:

• Risk modeling and actuarial tools.
• Population health analytics tied to real-time feeds.
• Care coordination automation and contract performance dashboards.

On the employer side, navigation and bundles players such as Transcarent and Carrum Health were frequent reference points in meetings. At the same time, we heard more investors and founders talk about employer-focused and self-insured strategies:

• Direct-to-employer specialty care services with outcomes tracking.
• Chronic condition management products that report both clinical and financial impact.
• Cost transparency and steerage platforms to help employers guide members to high-value care.

The rationale is straightforward: employers and plans often move faster than large health systems, which can accelerate traction and validate ROI.

8. Startup pavilion & pitch energy: what’s in, what’s out

ViVE’s startup pitch programming and floor energy made the new filter very visible.

What attracted real engagement from investors and health system buyers:

• Deep EHR / data integration instead of “sidecar” tools.
• Visible ROI or clinical outcomes within a reasonable timeframe.
• Clear strategies for compliance, security, and regulatory alignment.

Care automation platforms like Memora Health, primary care copilots such as Navina, and safety‑focused LLM efforts like Hippocratic AI all benefited from this ‘integrated + outcomes‑first’ filter.

What got much less traction:

• Consumer wellness apps without reimbursement or employer strategy.
• Generic AI chatbots that don’t change workflow or margin.
• Telehealth 2.0 offerings that look like existing services with no cost advantage.
• Growth-at-all-costs models with no clear path to unit economics.

The net effect: fewer hype-stage startups, more enterprise-ready solutions.

9. A few booth stories that capture the moment

Beyond themes and slides, a handful of encounters really captured where healthcare AI is heading:

• QuantalX — Delphi-MD
  A new modality for brain function assessment, FDA de novo–cleared and built for point-of-care use. It fills the “functional gap” between cognitive tests and structural imaging by using TMS-EEG to evaluate brain network integrity — with a workflow that looks much closer to EKG than to a traditional neuro workup.

• MyWaves
  Rather than diagnosing, myWaves positions itself purely as a wellness product: your own slow-wave sleep activity encoded into sound, delivered via an app in a simple nightly routine, with a clear subscription business model.

• Retia Medical
  A strong example of “AI as hemodynamic infrastructure,” leveraging signals hospitals already have to surface early circulatory risk in high-acuity patients, backed by FDA clearance and real-world deployments.

• Prodcycle
  A platform helping product and engineering teams in regulated industries (healthcare, finance) use AI coding agents safely — by baking HIPAA, SOC 2, GDPR and similar frameworks directly into product and technical requirement generation. It targets the meta-layer: AI about how you build AI.

• Bland
  A conversational voice AI platform for call centers across healthcare and other regulated industries. Their ViVE demo was simple and concrete: placing a coffee order by phone through a voice agent that captured the order, confirmed details like milk type, and pushed it straight to the barista — a small but effective illustration of end-to-end voice automation connected to back-end systems.

• Tombot
  A robotic emotional support companion already building significant preorder momentum, especially for dementia and serious health conditions, off the back of major visibility at CES. With B2C, senior living, and medical channels, it’s a hardware-plus-AI story with a tightly defined user and outcome.​

Together, these companies paint a picture of AI that is closer to the bedside (and bedside table), more regulated, more embedded, and more financially literate than in earlier cycles.

Macro signals from the floor

• Health systems are prioritizing automation over expansion.
• Employers are becoming faster early adopters than hospitals.
• Vertical AI is outperforming horizontal platforms in sales velocity.
• Infrastructure (data, security, interoperability) is back in the spotlight.
• FDA‑cleared tools are winning booth traffic over prototypes.

10. What ViVE 2026 means if you’re building in healthcare AI

Walking out of LACC, the message from ViVE 2026 felt less speculative and more operational:

• AI in healthcare is no longer about “if,” it’s “where does it fit in the P&L and the care pathway?”
• The strongest stories combine cost reduction, margin improvement, and clinical credibility.
• Vertical depth, interoperability, and regulatory awareness are now table stakes rather than differentiators.

If you’re building:

• Anchor your pitch in specific labor or margin wins — by role, by workflow, by time horizon.
• Be explicit about how you plug into existing systems (EHR, data platforms, security posture).
• Decide whether you’re a tool, a workflow, or infrastructure, and price and design accordingly.

ViVE 2026 didn’t just showcase the latest AI demos. It drew a much clearer line between what’s interesting to talk about — and what hospitals and investors are actually ready to buy.

The winners in this cycle won’t be the flashiest — they’ll be the teams who understand workflows, economics, and regulation as deeply as they understand models.